JP2019516707A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516707A5
JP2019516707A5 JP2018560460A JP2018560460A JP2019516707A5 JP 2019516707 A5 JP2019516707 A5 JP 2019516707A5 JP 2018560460 A JP2018560460 A JP 2018560460A JP 2018560460 A JP2018560460 A JP 2018560460A JP 2019516707 A5 JP2019516707 A5 JP 2019516707A5
Authority
JP
Japan
Prior art keywords
fibromyalgia
general formula
group
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516707A (ja
JP7071287B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2017/005173 external-priority patent/WO2017200318A1/ko
Publication of JP2019516707A publication Critical patent/JP2019516707A/ja
Publication of JP2019516707A5 publication Critical patent/JP2019516707A5/ja
Application granted granted Critical
Publication of JP7071287B2 publication Critical patent/JP7071287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560460A 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 Active JP7071287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2019516707A JP2019516707A (ja) 2019-06-20
JP2019516707A5 true JP2019516707A5 (cg-RX-API-DMAC7.html) 2020-06-25
JP7071287B2 JP7071287B2 (ja) 2022-05-18

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560460A Active JP7071287B2 (ja) 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用

Country Status (14)

Country Link
US (1) US10849882B2 (cg-RX-API-DMAC7.html)
EP (1) EP3459543B1 (cg-RX-API-DMAC7.html)
JP (1) JP7071287B2 (cg-RX-API-DMAC7.html)
KR (1) KR102489052B1 (cg-RX-API-DMAC7.html)
CN (1) CN109475529B (cg-RX-API-DMAC7.html)
AU (1) AU2017265839B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018073553A2 (cg-RX-API-DMAC7.html)
CA (1) CA3024286A1 (cg-RX-API-DMAC7.html)
DK (1) DK3459543T3 (cg-RX-API-DMAC7.html)
ES (1) ES2935596T3 (cg-RX-API-DMAC7.html)
MX (1) MX394245B (cg-RX-API-DMAC7.html)
PL (1) PL3459543T3 (cg-RX-API-DMAC7.html)
RU (1) RU2753525C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017200318A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
EP3711758B1 (en) 2017-11-14 2024-03-27 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure
KR102739580B1 (ko) * 2017-11-14 2024-12-06 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
ES3027977T3 (en) * 2017-11-14 2025-06-17 Sk Biopharmaceuticals Co Ltd Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
CA3116195A1 (en) * 2018-10-19 2020-04-23 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
IL293096A (en) * 2019-11-22 2022-07-01 Sk Biopharmaceuticals Co Ltd Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
US20030069306A1 (en) * 2001-07-16 2003-04-10 Codd Ellen C. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
MY155662A (en) * 2009-06-22 2015-11-13 Sk Biopharmaceuticals Co Ltd Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
JP5901528B2 (ja) * 2009-11-06 2016-04-13 エスケー バイオファーマスティカルズ カンパニー リミテッド 線維筋痛症候群の治療方法

Similar Documents

Publication Publication Date Title
JP2019516707A5 (cg-RX-API-DMAC7.html)
RU2494095C2 (ru) Модифицированные миметики лизина
JP2015532295A5 (cg-RX-API-DMAC7.html)
JP2020519661A5 (cg-RX-API-DMAC7.html)
JP2018524298A5 (cg-RX-API-DMAC7.html)
JP2015528471A5 (cg-RX-API-DMAC7.html)
RU2015143610A (ru) Лечение катаплексии
JP2014511892A5 (cg-RX-API-DMAC7.html)
RU2018144785A (ru) Применение соединения карбаминовой кислоты для профилактики или лечения фибромиалгии или функционального синдрома, ассоциированного с фибромиалгией
JP2016509047A5 (cg-RX-API-DMAC7.html)
JP2012530779A5 (cg-RX-API-DMAC7.html)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2015024998A5 (cg-RX-API-DMAC7.html)
RU2017112048A (ru) Синергистические комбинации ауристана
JP2013509441A5 (cg-RX-API-DMAC7.html)
JP2018523689A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3
JP2019516726A5 (cg-RX-API-DMAC7.html)
BRPI0618522A2 (pt) diaril uréia para o tratamento de hipertensão pulmonar
FI3506900T3 (fi) Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension
JP2016537432A5 (cg-RX-API-DMAC7.html)
EA201101305A1 (ru) Лечение рака поджелудочной железы
JP2019516722A5 (cg-RX-API-DMAC7.html)
RU2015113959A (ru) Индолины